3,4-Disubstituted isothiazoles: Novel potent inhibitors of VEGF receptors 1 and 2
作者:Alexander S. Kiselyov、Marina Semenova、Victor V. Semenov
DOI:10.1016/j.bmcl.2008.12.078
日期:2009.2
Novel derivatives of isothiazoles are described as potent ATP-competitive inhibitors of vascular endothelial growth factor receptors I and II (VEGFR-1/2). A number of compounds exhibited VEGFR-2 inhibitory activity comparable to that of Vatalanib™ in both HTRF enzymatic and cellular assays. Several derivatives featuring bulky meta-substituents in the amide portion of the molecule displayed 4- to 8-fold
异噻唑的新型衍生物被描述为血管内皮生长因子受体I和II(VEGFR-1 / 2)的有效ATP竞争性抑制剂。在HTRF酶和细胞分析中,许多化合物均具有与Vatalanib™相当的VEGFR-2抑制活性。几种在分子的酰胺部分具有较大的间位取代基的衍生物显示出对VEGFR-2的特异性是VEGFR-1的4到8倍。活性分子 在整个Caco-2细胞单层上也表现出高的固有渗透性(> 30×10 -5 cm / min)。